Package Insert: Information for the Patient
TENORMIN 0.5 mg/mL Injectable Solution
atenolol
Read this entire package insert carefully before you receive this medication, because it contains important information for you.
Tenormin 0.5 mg/ml injectable solution belongs to a group of medications called beta blockers, which act on your heart and circulatory system.
Tenormin 0.5 mg/ml injectable solution is indicated for the treatment of cardiac arrhythmias and acute myocardial infarction (early intervention in the acute phase).
Do not use Tenormin 0.5 mg/ml injectable solution:
Warnings and precautions
Consult your doctor or pharmacist before starting to use Tenormin 0.5 mg/ml injectable solution:
Children
It should not be used in children. See “Do not use Tenormin 0.5 mg/ml injectable solution”.
Use of Tenormin 0.5 mg/ml injectable solution with other medications
Inform your doctor or pharmacist if you are using, have used recentlyor may need to useany other medication, including those purchased without a prescription, homeopathic, herbal, and other health-related products, as it may be necessary to interrupt treatment or adjust the dose of one of them. Some medications may affect the action of others, particularly, inform your doctor if you are using:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy:
There is not enough data on the safety of Tenormin during the first month of pregnancy. Your doctor will decide if treatment during the second and third trimesters is beneficial for you.
Breastfeeding:
Inform your doctor if you are being treated with Tenormin 0.5 mg/ml injectable solution at the time of delivery or during breastfeeding, as your baby may be at risk of low blood sugar and slower heart rate.
Women breastfeeding should consult their doctor before taking this medication as atenololpasses into breast milk.
Important information about some of the components of Tenormin 0.5 mg/ml injectable solution:
Use in athletes:This medication contains atenolol, which may produce a positive result in doping control tests.
Follow exactly the administration instructions for this medication as indicated by your doctor.If in doubt, consult your doctor or pharmacist again.
Your doctor will inform you of the duration of your treatment with Tenormin 0.5 mg/ml injectable solution. Do not stop treatment before your doctor tells you to.
Tenormin 0.5 mg/ml injectable solution will be administered to you by your doctor or a nurse.
Your doctor will decide the dose of Tenormin 0.5 mg/ml injectable solution that will be injected and how often.
The injection will be administered intravenously.
The injection is normally administered in emergency situations. In many circumstances, you may continue to receive Tenormin in tablet form.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
For Tenormin administered in tablets over long periods of time, these side effects may be the following. Do not be alarmed by this list of possible adverse reactions, since if you have been administered the injection only for a short period of time (in emergency situations) you may not experience any of them:
Frequent:(affects between1and 10of every 100 patients)
Less frequent:(affects between1and 10of every 1,000 patients)
Rare (affects between1and 10of every 10,000 patients)
Very rare:(affects fewerthan 1 in 10,000 patients)
Frequency not known (cannot be estimated from available data):
If you consider that any of the side effects you experience are severe or if you notice any side effect not mentioned in this prospectus, inform your doctor or pharmacist.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Store the container protected from light, below 25°C.
Do not use this medication after the expiration date that appears on the box. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Tenormin 0.5 mg/ml injectable solution
Appearance of the product and contents of the packaging
This medication is presented in a package with 5 ampoules containing 5 mg of atenolol in 10 ml of isotonic aqueous solution buffered with citrate for intravenous administration.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Atnahs Pharma Netherlands B.V.
Copenhagen Towers
Ørestads Boulevard 108, 5th floor
DK-2300 København S
Denmark
Responsible for manufacturing:
Cenexi SAS
52 rue Marcel and Jacques Gaucher
94120 Fontenay Sous Bois
France
Last review date of this leaflet : May 2024
This information is intended solely for doctors or healthcare professionals
-------------------------------------------------------------------------------------------------------------------
Instructions for correct administration
No special handling is required. No incompatibilities have been described for this medication.
Tenormin 0.5 mg/ml injectable solution is compatible with sodium chloride 0.9% w/v and dextrose 5% w/v.
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.